Skip to main content
Fig. 2 | BMC Cardiovascular Disorders

Fig. 2

From: Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR)

Fig. 2

Changes in the use of renin-angiotensin system inhibitors after myocardial infarction in the Korean real-world. a All patients were required to remain on treatment, but 19% of patients receiving treatment with RASI stopped medication in the first year, b eighteen percent of patients receiving ACEIs stopped treatment in the first year and 33.4% of patients receiving ACEIs changed medication to ARBs, c fourteen percent of patients receiving ARBs stopped treatment in this real-world registry, while only about 1.5% switched from ARBs to ACEIs, d in patients not receiving RASI treatment, 24.5% began receiving ARBs and 8% began receiving ACEIs. RASI, renin-angiotensin system inhibitors; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; STEMI, ST segment elevation myocardial infarction

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us